Floatz logo

Nezastomig

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

229 Active assets in the Metastatic Castration-Resistant Prostate Cancer (mCRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Nezastomig is also rated in:

prostate cancerDormant
CC
Indicative ·
47 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
45 / 100
View asset →
nonpapillary renal cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →